Leading brokers name 3 ASX shares to buy today

Here's why brokers rate these ASX shares as buys…

| More on:
A white and black clock face is shown with three hands saying Time to Buy reflecting Citi's view that it's time to buy ASX 200 banks

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

With so many shares to choose from on the ASX, it can be hard to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work for you.

Three top ASX shares leading brokers have named as buys this week are listed below. Here's why they are bullish on them:

News Corp (ASX: NWS)

According to a note out of Goldman Sachs, its analysts have retained their conviction buy rating and increased their price target on this media giant's shares to $44.50. This follows the release of its full year result last week. And while News Corp fell a touch short of its expectations, the broker remains very positive on its outlook. It is forecasting operating earnings growth of 17% in FY 2022. It also believes share buybacks could unlock value for shareholders. The News Corp share price is trading at $32.37 today.

REA Group Limited (ASX: REA)

A note out of Morgan Stanley reveals that its analysts have retained their overweight rating and $185.00 price target on this property listings company's shares. Morgan Stanley was pleased with REA's FY 2021 result. And while it suspects that its first half result could be a touch softer than expected in FY 2022 because of lockdowns, it expects listing volumes to rebound quickly. In light of this, it appears to believe any short term share price weakness would be a buying opportunity. The REA share price is fetching $154.24 today.

ResMed Inc (ASX: RMD)

Analysts at Morgans have retained their add rating and lifted their price target on this sleep treatment company's shares by almost 42% to $41.34. This follows the release of a stronger than expected fourth quarter update last week. It also notes that management expects a US$300 million to US$350 million revenue benefit in FY 2022 from the product recall by rival Philips. The broker notes that this has led to unsatisfied demand everywhere. Though, Morgans acknowledges that bottlenecks in the supply chain could limit the benefit from pent-up demand for devices. The ResMed share price is trading at $37.77 today.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has recommended REA Group Limited and ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Broker Notes

A man looking at his laptop and thinking.
Broker Notes

Are WiseTech shares a buy after its big acquisition?

Let's see what analysts are saying about this tech stock.

Read more »

ASX 200 shares broker downgrade origami paper fortune teller with buy hold sell and dollar sign options
Broker Notes

Are Bendigo Bank shares a buy, hold or sell? Here's Macquarie's latest recommendation

Should I buy the dip on Bendigo Bank shares today?

Read more »

Happy man working on his laptop.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to snap up these shares.

Read more »

A female broker in a red jacket whispers in the ear of a man who has a surprised look on his face as she explains which two ASX 200 shares should do well in today's volatile climate
Broker Notes

5 of the best ASX 200 shares to buy in June

Let's see what brokers are recommending to investors for next month.

Read more »

A young man pointing up looking amazed, indicating a surging share price movement for an ASX company
Broker Notes

These ASX 200 shares could rise 20% to 100%

Analysts are expecting these shares to deliver big returns over the next 12 months.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

Broker looking at the share price.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A smiling woman at a hardware shop selects paint colours from a wall display.
Broker Notes

After its strategy day, what does Macquarie think Wesfarmers shares are worth?

Let's see what the broker is saying about this blue chip.

Read more »